Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Serotonergic drugs and valvular heart disease Rothman RB; Baumann MHExpert Opin Drug Saf 2009[May]; 8 (3): 317-29BACKGROUND: The serotonin (5-HT) releasers (+/-)-fenfluramine and (+)-fenfluramine were withdrawn from clinical use owing to increased risk of valvular heart disease. One prevailing hypothesis (i.e., the '5-HT hypothesis') suggests that fenfluramine-induced increases in plasma 5-HT underlie the disease. OBJECTIVE: Here, we critically evaluate the possible mechanisms responsible for fenfluramine-associated valve disease. METHODS: Findings from in vitro and in vivo experiments performed in our laboratory are reviewed. The data are integrated with existing literature to address the validity of the 5-HT hypothesis and suggest alternative explanations. CONCLUSIONS: The overwhelming majority of evidence refutes the 5-HT hypothesis. A more likely cause of fenfluramine-induced valvulopathy is activation of 5-HT(2B) receptors on heart valves by the metabolite norfenfluramine. Future serotonergic medications should be designed to lack 5-HT(2B) agonist activity.|Animals[MESH]|Fenfluramine/adverse effects/pharmacology[MESH]|Heart Valve Diseases/*chemically induced/metabolism[MESH]|Humans[MESH]|Receptor, Serotonin, 5-HT2B/metabolism[MESH]|Serotonin 5-HT2 Receptor Agonists[MESH]|Serotonin 5-HT2 Receptor Antagonists[MESH]|Serotonin Agents/*adverse effects/pharmacology[MESH]|Serotonin/metabolism[MESH] |
